1. Home
  2. VMD vs CTNM Comparison

VMD vs CTNM Comparison

Compare VMD & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Viemed Healthcare Inc.

VMD

Viemed Healthcare Inc.

HOLD

Current Price

$9.20

Market Cap

465.4M

Sector

N/A

ML Signal

HOLD

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

N/A

Current Price

$14.19

Market Cap

550.7M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
VMD
CTNM
Founded
2006
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
465.4M
550.7M
IPO Year
2018
2024

Fundamental Metrics

Financial Performance
Metric
VMD
CTNM
Price
$9.20
$14.19
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$19.00
AVG Volume (30 Days)
396.6K
323.2K
Earning Date
05-05-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
32.14
0.46
EPS
0.13
N/A
Revenue
$270,280,000.00
N/A
Revenue This Year
$17.88
N/A
Revenue Next Year
$14.98
N/A
P/E Ratio
$70.54
N/A
Revenue Growth
20.52
N/A
52 Week Low
$6.05
$7.26
52 Week High
$12.61
$16.91

Technical Indicators

Market Signals
Indicator
VMD
CTNM
Relative Strength Index (RSI) 23.46 47.45
Support Level $8.03 $13.23
Resistance Level $10.05 $15.69
Average True Range (ATR) 0.43 1.19
MACD -0.24 -0.09
Stochastic Oscillator 1.52 34.01

Price Performance

Historical Comparison
VMD
CTNM

About VMD Viemed Healthcare Inc.

Viemed Healthcare Inc is a provider of home medical equipment ("HME") and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women's health products and services. The Company's primary service offerings focus on effective in-home treatment, with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology. The company generates the majority of its revenue from medical equipment rental, sales, and supply.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Share on Social Networks: